A novel bile salts-lipase polymeric film-infused minitablet system for enhanced oral delivery of cholecalciferol.
Few researchers have investigated the use of multiple physiological enhancers combined with synthetic carriers to augment delivery of nutraceuticals. The current work describes the development of an oral delivery system termed a bioactive association platform (BAP) capable of delivering nutraceutical actives from a formulation framework specifically for enhancing the in vitro and in vivo performance of model vitamin, cholecalciferol (Vitamin D3). Synthesis of a novel triple vitamin minitablet and an optimized bile salt/lipase alginate-glycerin film provided unique oral components for inclusion in a BAP capsule. Component validation and physicochemical characterizations included comparative ex vivo permeability, chemical structure mapping, thermodynamic analysis and magnetic resonance imaging. In vitro dissolution studies of the BAP produced an area under the dissolution curve (AUC) for cholecalciferol release that was 28% greater than a conventional comparator product. A total of 84.01% of cholecalciferol was released from the BAP within 3 h versus only 59% from a comparator. Ex vivo permeation studies revealed superior cholecalciferol membrane diffusion from the triple vitamin minitablet BAP component. In vivo performance showed a greater mean change from baseline cholecalciferol to peak plasma levels (Cmax) from the BAP compared to the comparator (55.66 versus 46.05 ng/mL). Cholecalciferol bioavailability was improved in vivo with an AUC0-inffrom the BAP that was 3.2× greater than the conventional product. The BAP was also superior at improving and maintaining serum levels of the main metabolite, 25-hydroxyvitamin D3, compared to the conventional system. In vitro and in vivo results thus confirmed improvements in cholecalciferol dissolution, membrane permeability and plasma drug levels. The study results position the BAP as an ideal oral vehicle for enhanced delivery of cholecalciferol.
a Wits Advanced Drug Delivery Platform Research Unit, Department of Pharmacy and Pharmacology, Faculty of Health Sciences, School of Therapeutic Sciences, University of the Witwatersrand , Johannesburg , Parktown , South Africa.
Miles C
MC
Braithwaite
a Wits Advanced Drug Delivery Platform Research Unit, Department of Pharmacy and Pharmacology, Faculty of Health Sciences, School of Therapeutic Sciences, University of the Witwatersrand , Johannesburg , Parktown , South Africa.
Yahya E
YE
Choonara
a Wits Advanced Drug Delivery Platform Research Unit, Department of Pharmacy and Pharmacology, Faculty of Health Sciences, School of Therapeutic Sciences, University of the Witwatersrand , Johannesburg , Parktown , South Africa.
Pradeep
P
Kumar
a Wits Advanced Drug Delivery Platform Research Unit, Department of Pharmacy and Pharmacology, Faculty of Health Sciences, School of Therapeutic Sciences, University of the Witwatersrand , Johannesburg , Parktown , South Africa.
Lomas K
LK
Tomar
a Wits Advanced Drug Delivery Platform Research Unit, Department of Pharmacy and Pharmacology, Faculty of Health Sciences, School of Therapeutic Sciences, University of the Witwatersrand , Johannesburg , Parktown , South Africa.
Lisa C
LC
Du Toit
a Wits Advanced Drug Delivery Platform Research Unit, Department of Pharmacy and Pharmacology, Faculty of Health Sciences, School of Therapeutic Sciences, University of the Witwatersrand , Johannesburg , Parktown , South Africa.
Viness
V
Pillay
D000284:Administration, Oral; D000818:Animals; D001647:Bile Acids and Salts / Q000737:chemistry*; D001682:Biological Availability; D002214:Capsules / Q000008:administration & dosage / Q000737:chemistry / Q000378:metabolism; D002626:Chemistry, Pharmaceutical / Q000379:methods; D002762:Cholecalciferol / Q000008:administration & dosage* / Q000737:chemistry* / Q000378:metabolism; D016503:Drug Delivery Systems / Q000379:methods; D005079:Excipients / Q000737:chemistry; D008049:Lipase / Q000737:chemistry*; D010539:Permeability; D011108:Polymers / Q000737:chemistry*; D012995:Solubility; D013552:Swine; D013607:Tablets / Q000008:administration & dosage* / Q000737:chemistry* / Q000378:metabolism; D014807:Vitamin D / Q000031:analogs & derivatives / Q000737:chemistry; D014815:Vitamins / Q000008:administration & dosage / Q000737:chemistry
D001647:Bile Acids and Salts; D002214:Capsules; D005079:Excipients; D011108:Polymers; D013607:Tablets; D014815:Vitamins; D014807:Vitamin D; D002762:Cholecalciferol; C104450:25-hydroxyvitamin D; D008049:Lipase
Bile salts; bioavailability enhancement; cholecalciferol; digestive co-factors; pancreatic lipase; physicochemical properties; solubility and absorption enhancers; vitamins